When an important concept puts a scientific paper under the spotlight, behind the scenes there is usually a long story of mystery solving, as Philip Petersen explains.

Maze is advancing an APOL1 small molecule inhibitor program, with preclinical data demonstrating dose dependent responses to treatment and supporting its potential as a treatment for certain APOL1 ...

The maze has passages of varying width, and they travel in all odd directions (not the cardinal up down left right.) ...